tbuckley/cabot-search huggingface dataset:
Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status
Authors: Cecelia Miller, Ying Huang, Jonathan Hyak, Matthew R Avenarius, Amy S. Ruppert, John C. Byrd, Seema A Bhat, Michael R Grever, Adam S Kittai, Kerry Rogers, Nyla A. Heerema, Lynne V. Abruzzo, Jennifer A. Woyach
Journal: Blood (2021)
Sex Impacts Disease Activity But Not Symptoms or Quality of Life in Adults With Eosinophilic Esophagitis
Authors: Philipp Schreiner, Ekaterina Safroneeva, Jean-Benoit Rossel, Andreas Limacher, Catherine Saner, Thomas Greuter, Alain Schoepfer, Alex Straumann, Luc Biedermann
Journal: Clinical Gastroenterology and Hepatology (2021)
Determinants of the adoption of injury risk reduction programmes in athletics (track and field): an online survey of 7715 French athletes
Authors: Alexis Ruffault, Marine Sorg, Simon Martin, Christine Hanon, Lison Jacquet, Evert Verhagen, Pascal Edouard
Journal: British Journal of Sports Medicine (2021)

To identify individual characteristics associated with the adoption of injury risk reduction programmes (IRRP) and to investigate the variations in sociocognitive determinants (ie, attitudes, subjective norms, perceived behavioural control and intentions) of IRRP adoption in athletics (track and field) athletes.We conducted a cross-sectional study using an online survey sent to athletes licensed with the French Federation of Athletics to investigate their habits and sociocognitive determinants of IRRP adoption. Sociodemographic characteristics, sports practice and history of previous injuries were also recorded. Logistic regression analyses and group comparisons were performed.The final sample was composed of 7715 athletes. From the multivariable analysis, competing at the highest level was positively associated with IRRP adoption (adjusted OR (AOR)=1.66; 99.9% CI 1.39 to 1.99 and AOR=1.48; 99.9% CI 1.22 to 1.80) and presenting a low number of past injuries was negatively associated with IRRP adoption (AOR=0.48; 99.9% CI 0.35 to 0.65 and AOR=0.61; 99.9% CI 0.44 to 0.84), both during their lifetime and the current season, respectively. These results were supported by higher scores of sociocognitive determinants among athletes who reported IRRP adoption compared with other athletes.Some characteristics of athletes seem to be associated with IRRP adoption either positively (competing at the highest level) or negatively (presenting a lower number of past injuries), whereas all the sociocognitive determinants tested appear to be linked to IRRP adoption. Since many athlete characteristics are difficult or impossible to change, IRRP promotion may be enhanced by targeting athletes' beliefs and intentions to adopt an IRRP.
A Real-World Canadian Experience of Asciminib Use in Chronic Myeloid Leukemia (CML) Patients Who Failed Multiple Lines of Tyrosine Kinase Inhibitor (TKI) Therapy
Authors: Fatima Khadadah, Anargyros Xenocostas, Lambert Busque, Kareem Jamani, Sonia Cerquozzi, Philip Kuruvilla, Brian Leber, Rayan Kaedbey, Sarit Assouline, Dennis Dong Hwan Kim
Journal: Blood (2021)
Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis
Authors: Orly Leiva, Duaa AbdelHameid, Jean M. Connors, Christopher P. Cannon, Deepak L. Bhatt
Journal: JACC CardioOncology (2021)

Cardiovascular disease and cancer are the 2 leading causes of death worldwide. Emerging evidence suggests common mechanisms between cancer and cardiovascular disease, including atrial fibrillation and atherosclerosis. With advances in cancer therapies, screening, and diagnostics, cancer-specific survival and outcomes have improved. This increase in survival has led to the coincidence of cardiovascular disease, including atrial fibrillation and atherosclerosis, as patients with cancer live longer. Additionally, cancer and cardiovascular disease share several risk factors and underlying pathophysiologic mechanisms, including inflammation, cancer-related factors including treatment effects, and alterations in platelet function. Patients with cancer are at increased risk for bleeding and thrombosis compared with the general population. Although optimal antithrombotic therapy, including agent choice and duration, has been extensively studied in the general population, this area remains understudied in patients with cancer despite their altered thrombotic and bleeding risk. Future investigation, including incorporation of cancer-specific characteristics to traditional thrombotic and bleeding risk scores, clinical trials in the cancer population, and the development of novel antithrombotic and anti-inflammatory strategies on the basis of shared pathophysiologic mechanisms, is warranted to improve outcomes in this patient population.
Abstract 9541: Sex Disparities in In-Hospital Outcomes of Left Ventricular Aneurysm Complicating Acute Myocardial Infarction: A United States Nationwide Analysis
Authors: Venkata Siva Kumar Pajjuru, Abhishek Thandra, Ryan Walters, Bhavani Nagendra N Papudesi, Saraschandra Vallabhajosyula, Venkata M Alla, Andrew M Goldsweig
Journal: Circulation (2021)

Background: Previous studies have reported sex-specific differences in the presentation, mechanisms, and outcomes of acute myocardial infarction (AMI). Objective: To assess differences in the incidence and in-hospital outcomes of left ventricular (LV) aneurysm complicating AMI in women and men. Methods: We used the National Inpatient Sample database (NIS) from 2000 to 2017, to identify adult hospitalizations with a primary diagnosis of AMI and concomitant LV aneurysm. Incidence and trends in in-hospital mortality, complications, length of stay and costs were analyzed in women and men. Results: A total of 16,334 AMI hospitalizations with LV aneurysm were identified including 6,994 (42.8%) women and 9,340 (57.2%) men. Women had a higher incidence of LV aneurysm compared to men (0.16% vs. 0.14%; p&lt;0.001). Compared to men, women were older (73 [63-81] vs 65 [56-75]; p&lt;0.001), black race (9.6% vs 7.4%; p=0.1), and have higher elixhauser comorbidity index (2 [-1 to 9] vs 0 [-1 to 8]; p=0.014). Unadjusted in-hospital mortality was higher in women than men (12.7% vs. 7.2%; p&lt;0.001). After adjusting for demographic and baseline characteristics and excluding inter-hospital transfers, women with AMI complicated by LV aneurysm had 49% greater odds of in-hospital mortality than men (aOR 1.49, 95% Confidence Interval 1.06-2.10, p=0.02). Women with LV aneurysm were less likely than men to undergo percutaneous coronary intervention (28.5% vs. 35.4%; p&lt;0.001), bypass surgery (15.8% vs. 25.1%; p&lt;0.001), coronary atherectomy (0.8% vs. 1.9%; p=0.009) and LV aneurysm surgery (7.8% vs. 11.1%; p=0.001). Conclusions: In this large population-based cohort study, women had a slightly higher incidence but dramatically higher in-hospital mortality associated with LV aneurysm complicating AMI compared to men. Further research is necessary to validate strategies to ensure that women receive guideline-directed therapy for AMI and LV aneurysm to address the sex disparity in mortality.
Lentiviral Gene Therapy for the Correction of Congenital Dyserythropoietic Anemia Type II
Authors: Mercedes Dessy-Rodriguez, Sara Fañanas-Baquero, Veronica Venturi, Salvador Payan, Cristian Tornador, Gonzalo Hernández, Paola Bianchi, Mayka Sanchez, Juan Carlos Ramirez, José C Segovia, Oscar Quintana Bustamante
Journal: Blood (2021)
Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group
Authors: Marie Sebert, Thomas Cluzeau, Odile Beyne Rauzy, Aspasia Stamatoulas Bastard, Sophie Dimicoli-Salazar, Sylvain Thepot, Pierre Peterlin, Sophie Park, Marie-Pierre Gourin, Oana Brehar, Cécile Bally, Sébastien Maury, Gaelle Fossard, Lamya Ait Si Selmi, Cendrine Chaffaut, Emmanuelle Clappier, Raphael Itzykson, Fatiha Chermat, Sylvie Chevret, Pierre Fenaux, Lionel Ades
Journal: Blood (2021)
Abstract 9211: Utility of Transthoracic Echocardiography in Hospitalized Patients With Stroke or Transient Ischemic Attack
Authors: Vahid Namdarizandi, Bassman Tappuni, Ali AlKhayru, Awfa Elabidin, Leanne Pereira, Michael Fatuyi, Vivek Sharma, Belal Kaseer, Dominique Brandt, Kamal Shemisa
Journal: Circulation (2021)

Background: Stroke is a leading cause of mortality in the US. The AHA/ASA Stroke Guidelines recommend echocardiography (ECHO) as part of cardiac evaluation for prevention of recurrent stroke. This study investigated the utility and associated cost of TTE as a diagnostic tool in stroke or TIA. Methods: A retrospective study of adults admitted with a diagnosis of stroke or TIA was conducted from 2016-2019 using the Trihealth EHR. Patient characteristics, comorbidities, TTE findings were analyzed using descriptive statistics. Hospital total cost &amp; length of stay (LOS) were compared between patients with &amp;without TTE using Mann-Whitney test. Results: There were 3,894 patients hospitalized with a stroke or TIA. A TTE was ordered for 2,435 (2,202 stroke, 233 TIA). Among stroke patients, the Median (IQR) age was 71 (60-81), 52% were female, 76% had hypertension, 57% history of tobacco &amp; 39% had Diabetes. TTE abnormalities were found in 74% with LVH or LA dilation most common and MVP or PFO least common (figure 1). Ejection fraction was normal in 83%, borderline in 5.5% &amp; reduced in 6.4%. Median (IQR) hospitalization cost was lower in the TTE group 7,153 [4,754-12,412] vs.7,733 [4,754-12,412], p=0.009, but not LOS, 3[2-5] vs. 3[2-6], p=0.212. Conclusion: Echocardiogram abnormalities were prevalent in patients hospitalized with stroke/TIA. Abnormalities ranged from LVH or LA dilatation being most common to MVP or PFO least common. The evaluation with TTE in stroke &amp; TIA patients may be cost saving. Further investigation is necessary.
A Longitudinal Evaluation of Cytopenia Severity in Patients with Clonal Cytopenia of Undetermined Significance (CCUS) and Correlation with the Presence of Sub-Clinical Dysplasia
Authors: Michael Daunov, Howard Meyerson, Kwadwo Asare Oduro, Christopher B Ryder, Navid Sadri, Jennifer Yoest, Shufen Cao, Pingfu Fu, Rose Beck, Benjamin Tomlinson
Journal: Blood (2021)
The CXCL1 Inhibitor Reparixin Rescues Myelofibrosis in the <i>Gata1</i>low Model of the Disease
Authors: Paola Verachi, Fabrizio Martelli, Maria Zingariello, Francesca Gobbo, Giuseppe Sarli, John D. Crispino, Maria Teresa Massucci, Laura Brandolini, Cristina Giorgio, Marcello Allegretti, Anna Rita Migliaccio
Journal: Blood (2021)
A Durable Anatomy with Local Plasticity Enables Normal and Stress Hematopoiesis
Authors: Qingqing Wu, Jizhou Zhang, Courtney Johnson, Benjamin Weinhaus, Anastasiya Slaughter, Andre Valladares-Nuñez, Andre Sherman, Marie-Dominique Filippi, Surya Prasath Vellai Badradoss, Sing Sing Way, J. Mathew Koffron, Daniel Lucas-Alcaraz
Journal: Blood (2021)
Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study
Authors: Jessica K. Altman, Jamie Koprivnikar, James K McCloskey, Vamsi Kota, Michael Keng, Dale L. Bixby, Olga Frankfurt, Ashkan Emadi, Tsila Zuckerman, Micah M. Burch, Moshe Y. Levy, Selina M. Luger, Bhavana Bhatnagar, Ofir Wolach, Chezi Ganzel, Mary-Beth M. Percival, Gail J. Roboz, Michael Craig, Itai Levi, Anna Gourevitch, Liat Flaishon, Darrel P. Cohen, Shoshi Tessler, Chen Blumberg, Stela Gengrinovitch, Ruth Ben Yakar, Jacob M. Rowe
Journal: Blood (2021)
Complex Clonal Evolution Can Occur Following Transplantation for Transfusion Dependent Thalassaemia in the Context of Mixed Myeloid Chimerism and Reduced Conditioning Regimens
Authors: Adam Gassas, Farah O'Boyle, Shahzya Chaudhury, Toni Petterson, Kirstin Lund, Leena Karnik, Josu de la Fuente
Journal: Blood (2021)
Bisphosphonate-based hydrogel mediates biomimetic negative feedback regulation of osteoclastic activity to promote bone regeneration
Authors: Zhuo Li, Haixing Wang, Kunyu Zhang, Boguang Yang, Xian Xie, Zhengmeng Yang, Lingchi Kong, Peng Shi, Yuan Zhang, Yi-Ping Ho, Zhi-Yong Zhang, Gang Li, Liming Bian
Journal: Bioactive Materials (2021)

The intricate dynamic feedback mechanisms involved in bone homeostasis provide valuable inspiration for the design of smart biomaterial scaffolds to enhance in situ bone regeneration. In this work, we assembled a biomimetic hyaluronic acid nanocomposite hydrogel (HA-BP hydrogel) by coordination bonds with bisphosphonates (BPs), which are antiosteoclastic drugs. The HA-BP hydrogel exhibited expedited release of the loaded BP in response to an acidic environment. Our in vitro studies showed that the HA-BP hydrogel inhibits mature osteoclastic differentiation of macrophage-like RAW264.7 cells via the released BP. Furthermore, the HA-BP hydrogel can support the initial differentiation of primary macrophages to preosteoclasts, which are considered essential during bone regeneration, whereas further differentiation to mature osteoclasts is effectively inhibited by the HA-BP hydrogel via the released BP. The in vivo evaluation showed that the HA-BP hydrogel can enhance the in situ regeneration of bone. Our work demonstrates a promising strategy to design biomimetic biomaterial scaffolds capable of regulating bone homeostasis to promote bone regeneration.
Prevention of Acute Graft-Versus-Host Disease Using an Engineered Mouse Orthogonal IL-2/IL-2Rβ Regulatory T Cells
Authors: Teresa Lopes Ramos, Sara B. Wagers, Po-Yu Lin, Toshihito Hirai, Leon Su, Lora Picton, Jeanette Baker, Juliane Lohmeyer, Melissa Mavers, Christopher Garcia, Bruce R. Blazar, Robert S. Negrin
Journal: Blood (2021)
Sustained Delivery of SARS‐CoV‐2 RBD Subunit Vaccine Using a High Affinity Injectable Hydrogel Scaffold
Authors: Jing Chen, Bo Wang, Julia S. Caserto, Kaavian Shariati, Peng Cao, Yang Pan, Qixuan Xu, Minglin Ma
Journal: Advanced Healthcare Materials (2021)

Abstract The receptor binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) spike protein that mediates viral entry into host cells is a good candidate immunogen for vaccine development against coronavirus disease 2019 (COVID‐19). Because of its small size, most preclinical and early clinical efforts have focused on multimerizing RBD on various formats of nanoparticles to increase its immunogenicity. Using an easily administered injectable hydrogel scaffold that is rationally designed for enhanced retainment of RBD, an alternative and facile approach for boosting RBD immunogenicity in mice is demonstrated. Prolonged delivery of poly (I:C) adjuvanted RBD by the hydrogel scaffold results in sustained exposure to lymphoid tissues, which elicits serum IgG titers comparable to those induced by three bolus injections, but more long‐lasting and polarized toward T H 1‐mediated IgG2b. The hydrogel scaffold induces potent germinal center (GC) reactions, correlating with RBD‐specific antibody generation and robust type 1 T cell responses. Besides being an enduring RBD reservoir, the hydrogel scaffold becomes a local inflammatory niche for innate immune cell activation. Collectively, the injectable hydrogel scaffold provides a simple, practical, and inexpensive means to enhance the efficacy of RBD‐based subunit vaccines against COVID‐19 and may be applicable to other circulating and emerging pathogens.
Clinical Significance of Mitochondrial DNA Content in Acute Promyelocytic Leukemia
Authors: Antonio R. Lucena-Araujo, Diego A Pereira-Martins, Juan L Coelho-Silva, Isabel Weinhäuser, Pedro Luis Franca-Neto, Douglas RA Silveira, Marinus M Lima, Jan Jacob Schuringa, Luisa C Koury, Raul Antônio Morais Melo, Rosane Bittencourt, Katia B Pagnano, Elenaide C. Nunes, Evandro Maranhão Fagundes, Fabio R. Kerbauy, Lorena Figueredo-Pontes, Eduardo M Rego
Journal: Blood (2021)
Characterizing Safety in Patients with Hematologic Malignancies Receiving Allogeneic Stem Cell Transplant (Allo-SCT) Following Pembrolizumab Therapy
Authors: Philippe Armand, John Kuruvilla, Alex F. Herrera, Vincent Ribrag, Pauline Brice, Catherine Thieblemont, Bastian Von Tresckow, Eunhee Kim, Robert Orlowski, Samhita Chakraborty, Patricia Marinello, Pier Luigi Luigi Zinzani
Journal: Blood (2021)
Abstract 9140: Validity of Coronary Angiography-Based Physiology in Clinical Practice
Authors: Luciano de Moura Santos, wenderval B carvalho junior, Marcelo H Ribeiro, Maria Antonieta A Lopes, Julia T Fukushima, Alexandre A Abizaid, Carlos M Campos
Journal: Circulation (2021)

Introduction: The invasive physiological assessment of the severity of coronary obstruction is performed by hyperemic (FFR) and non-hyperemic (iFR) indices. However, the need to insert an intracoronary pressure guidewire are factors that limit its use. Quantitative flow ratio (QFR) is a method that infers the value of FFR, eliminating the use of a pressure wire and coronary hyperemia. Objectives: Evaluate the diagnostic accuracy of the QFR, diameter stenosis percentual (DS%) and area stenosis percentual (AS%) in comparison with the FFR, for identification of significant obstructive coronary lesions (FFR ≤ 0.80) and the feasibility to assess QFR in cohort of patients without dedicated angiographic acquisition. Methods: Consecutive patients with moderate obstructive lesions in coronary angiography that had previous FFR measurement were evaluated. Validation of QFR was assessed by accuracy, area under the curve (AUC), sensitivity, specificity, correlation coefficient and Bland-Altman plot, using FFR as reference method. Results: Out of 102 patients and 143 arteries assessed by the FFR, only 69 (67%) patients and 75 (52%) arteries were possible to be calculated by QFR. The accuracy of the QFR to detect an FFR ≤ 0.80 was 84.0% (95% CI: 75.6% to 92.4%), with a sensitivity of 67.9% (95% CI: 47.6% to 84.1%) and specificity of 93.6% (95% CI: 82.5% to 98.7%). The correlation and agreement between FFR and QFR were r = 0.54, p &lt; 0.01 and mean difference = -0.02 ± 0.09; p = 0.0874, respectively. The AUC to QFR, DS% and AS% comparison are represented in the attached figure. Conclusions: QFR demonstrated good accuracy and agreement, compared to the FFR, with moderate correlation in an unselected population of clinical practice. QFR and DS% demonstrated AUC greater than AS%. However, the high rate of exclusion in offline evaluations of angiograms recorded without dedicated acquisition protocol considerably limits the use of this tool in clinical practice.
Sustained Improvements in Patient-Reported Quality of Life up to 24 Months Post-Treatment with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy
Authors: Mark C. Walters, John F. Tisdale, Markus Y. Mapara, Lakshmanan Krishnamurti, Janet L. Kwiatkowski, Banu Aygun, Kimberly A. Kasow, Stacey Rifkin-Zenenberg, Jennifer Jaroscak, Diana Garbinsky, Costel Chirila, Meghan E. Gallagher, Xinyan Zhang, Pei-Ran Ho, Alexis A. Thompson, Julie Kanter
Journal: Blood (2021)
29 Elevated Flt3L predicts long-term survival in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms
Authors: Katharina Detjen, Raik Otto, Yvonne Giesecke, Lukas Geisler, Pamela Riemer, Henning Jann, Carsten Grötzinger, Christine Sers, Tom Luedde, Ulf Leser, Bertram Wiedenmann, Michael Sigal, Frank Tacke, Christoph Roderburg, Linda Hammerich
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are a rare and heterogeneous family of tumors arising from the disseminated neuroendocrine system of the gastrointestinal tract and pancreas. Clinical management of high-grade GEP-NEN is challenging due to disease heterogeneity, illustrating the need for reliable biomarkers facilitating patient stratification and guiding treatment decisions. FMS-like tyrosine kinase 3 ligand (Flt3L) is emerging as a prognostic or predictive surrogate marker of host tumoral immune response and might enable stratification of patients with otherwise comparable tumor features. Methods We used RNAseq data from human foregut-derived pancreatic and gastric GEP-NEN to evaluate Flt3L gene expression in tumor tissue. The data set (n=54) represented the full range of NEN grades and differentiation, and expression levels were compared to healthy control tissue as well. We also analyzed circulating Flt3L levels in serum samples of a separate cohort of G2/G3 GEP-NEN (n=59) an healthy controls (n=4). The study was approved by the local ethics committee at Charité Universitätsmedizin Berlin, Germany (ethical approval number EA1/229/17) and patient informed consent was obtained. Results We detected a prominent induction of Flt3L gene expression in individual G2 and G3 NEN, but not in G1 neuroendocrine tumors (NET). Flt3L mRNA expression levels in tumor tissue predicted disease related survival of patients with highly proliferative G2 and G3 NEN more accurately than the conventional criteria of grading or NEC/NET differentiation. High level Flt3L mRNA expression was associated with increased expression of genes related to immunogenic cell death, lymphocyte effector function and dendritic cell maturation, suggesting a less tolerogenic (more proinflammatory) phenotype of tumors with Flt3L induction. Importantly, circulating levels of Flt3L were also elevated in high grade NEN and correlated with patients´ progression-free and disease-related survival, thereby reflecting the results observed in tumor tissue. Conclusions Our results suggest Flt3L as a surrogate marker of an inflammatory tumor microenvironment. Therefore, we propose Flt3L as a prognostic biomarker for high grade GEP-NEN. Flt3L measurements in serum, which can be easily be incorporated into clinical routine, may hold the promise to guide patient stratification and tailor treatment decisions and should be further evaluated, especially in the context of immunotherapies. Ethics Approval The study was approved by the local ethics committee at Charité Universitätsmedizin Berlin, Germany (ethical approval number EA1/229/17) and patient informed consent was obtained.
Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience
Authors: Lorenzo Falchi, Annie Qiu, Mark D. Ewalt, Connie Lee Batlevi, Philip C Caron, Paul A. Hamlin, Audrey Hamilton, Steven M. Horwitz, Erel Joffe, Niloufer Khan, Anita Kumar, Alison J. Moskowitz, Ariela Noy, Colette Owens, Maria Lia Palomba, David J. Straus, Gottfried von Keudell, Andrew D. Zelenetz, Ahmet Dogan, Klaus Busam, Patricia Myskowski, Joachim Yahalom, Gilles Salles, Matthew J. Matasar
Journal: Blood (2021)
Global Waldenström's Macroglobulinemia Patient-Derived Data Registry, Whimsical, Highlights Real-World Treatment Outcomes and COVID-19 Data
Authors: Ibrahim Tohidi-Esfahani, Andrew Warden, Elena Malunis, Peter Liburdi deNardis, Michelle Postek, Shirley D'Sa, Marie José Kersten, Sheeba K Thomas, M. Lia Palomba, Adam J. Olszewski, Newton Guerin, Clare Scott, Judith Trotman
Journal: Blood (2021)
Glecaprevir/Pibrentasvirによる治療の8週間は,C型肝炎ウイルス感染を伴う治療未経験患者の統合分析において安全かつ有効である【JST・京大機械翻訳】
Authors: Zuckerman Eli, A Gutierrez Julio, E Dylla Douglas, de Ledinghen Victor, J Muir Andrew, Gschwantler Michael, Puoti Massimo, Caruntu Florin, Slim Jihad, Nevens Frederik, Sigal Samuel, Cohen Stanley, M Fredrick Linda, Pires dos Santos Ana Gabriela, Rodrigues Lino, F Dillon John
Journal: Clinical Gastroenterology and Hepatology (2020)
Anti-B7-H3 Antibody (T-1A5) Blocks Immunomodulatory Function of B7-H3 and Enhances NK Cell-Mediated Cytotoxicity Against Acute Myeloid Leukemia Cells
Authors: Anudishi Tyagi, Stanley Ly, Fouad El-Dana, Bin Yuan, Sabrina Grimm, Hans-Jörg Bühring, Venkata Lokesh Battula
Journal: Blood (2021)